Pharmacyte Biotech Inc (PMCB) Stock Price, Quote & News

Company Profile

PharmaCyte Biotech, Inc., a biotechnology company, focused on developing and preparing to commercialize cellular therapies for cancer using live cell encapsulation technology in the United States. The company's cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer. It also develops CypCaps for pancreatic cancer and other soli...

Industry: Biotechnology

Sector: Healthcare

Phone: 917 595 2850

Fax: 917 595 2851

Website: pharmacyte.com

Address:

3960 Howard Hughes Parkway, Suite 500, Las Vegas, United States

BillionerOfKing Nov. 11 at 3:43 PM

$PMCB Current Stock Price: $0.88 Contracts to trade: $2.5 PMCB Nov 21 2025 Call Entry: $0.05 Exit: $0.06 ROI: 28% Hold ~25 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

Dfastpitchchic5 Nov. 5 at 10:19 PM

$PMCB

0 · Reply

NicoleToki632 Nov. 4 at 4:35 PM

$PMCB shows strategic interest in AI-enhanced monitoring and analytics as AITX adds a major U.S. healthcare system client, moving from pilot to paid deployments as hospitals adopt RIO 360 units to enhance safety and efficiency.

0 · Reply

SwingNow Oct. 31 at 5:01 PM

My pick going into next week are $GSIW $ITP $PMCB $IVF . All this four gonna spike soon have fun

0 · Reply

ChaseDeluca Oct. 31 at 12:56 PM

QCLS just changed game‑plans: quantum‑class photonics + blockchain infrastructure = a combo most aren’t even aware of yet. With float under ~2M shares and short interest elevated, the risk to the upside is huge. $ALDX $PMCB $MNPR $RGTI

0 · Reply

ChaseDeluca Oct. 30 at 9:16 PM

QCLS is still priced like a ghost ticker… But today’s quantum + blockchain news puts it in a league of its own. Microscopic float. Breakout structure. This is how $1–$10 stories begin silently, then all at once. $PMCB $IQST $ACER $MNPR

0 · Reply

BHWinehouse Oct. 30 at 1:41 PM

$QCLS $PMCB

0 · Reply

BirchTreeJJ Oct. 28 at 12:15 PM

$PMCB $QCLS buyout of assets

0 · Reply

BHWinehouse Oct. 28 at 11:46 AM

$PMCB PharmaCyte Biotech, Inc. (NASDAQ: PMCB) Special Meeting of Stockholders scheduled for Thursday, October 30, 2025 at 11:00 a.m. ET. Could be interesting $QCLS

0 · Reply

BHWinehouse Oct. 24 at 4:12 PM

$QCLS Yep, that's it! Nothing to do with obtaining exclusive rights to Lightsolver photonics tech saving companies like $MARA 90% on energy or the fact they have MYMD-1 that is ready to enter Ph2 clinical trials which will most likely be sold to $PMCB since they already have $7M invested in it and we the same "ceo". Nothing really to see here....

0 · Reply

PharmaCyte Biotech, Inc. Increases Stake in TNF Pharmaceuticals Around Recent License for Breakthrough Light Speed Computing Platform for Use in Cryptocurrency Applications

Aug 20, 2025, 9:15 AM EDT - 3 months ago

PharmaCyte Biotech, Inc. Announces Closing of $7 Million Financing

Aug 18, 2025, 9:15 AM EDT - 3 months ago

PharmaCyte Biotech, Inc. Announces $7 Million Capital Raise Led by Existing Investors

May 21, 2024, 9:00 AM EDT - 1 year ago

MyMD Pharmaceuticals Secures Strategic Investments

May 21, 2024, 9:00 AM EDT - 1 year ago

PharmaCyte Biotech Makes $7 Million Strategic Investment in MyMD, A Biopharmaceutical Company Focused on Inflammatory Disease

Nov 15, 2023, 8:30 AM EST - 2 years ago

PharmaCyte Biotech Acquires $5 Million Stake in Emerging Women's Health Innovator Femasys, Inc.

FEMY

Oct 31, 2023, 9:15 AM EDT - 2 years ago

PharmaCyte Biotech Provides Corporate Update on Cell-in-a-Box Technology

Jun 15, 2023, 9:15 AM EDT - 2 years ago

PharmaCyte Biotech Announces Final Results of Tender Offer

May 11, 2023, 8:30 AM EDT - 2 years ago

PharmaCyte Biotech Announces Cash Tender Offer for up to 7,750,000 Shares at $3.25 Per Share

Feb 2, 2023, 9:00 AM EST - 3 years ago

PharmaCyte Biotech to Implement Second $10-Million Share Repurchase Plan

Oct 7, 2022, 9:00 AM EDT - 3 years ago

PharmaCyte Biotech Board of Directors Announces Business Review Committee to Evaluate Opportunities to Optimize Shareholder Value

Aug 15, 2022, 8:30 AM EDT - 3 years ago

PharmaCyte Biotech Reaches Cooperation Agreement with Iroquois Capital

Jul 28, 2022, 12:49 PM EDT - 3 years ago

PharmaCyte Biotech Rebukes Iroquois' Commencement of Consent Solicitation

Jul 28, 2022, 9:00 AM EDT - 3 years ago

Iroquois Files Preliminary Consent Materials to Reconstitute Board of Directors at PharmaCyte Biotech, Inc.

Jul 21, 2022, 8:30 AM EDT - 3 years ago

PharmaCyte Biotech Commences First Phase of Two-Phase Pig Study

Jul 19, 2022, 8:30 AM EDT - 3 years ago

PharmaCyte Biotech Reports Positive Interim Results in Malignant Ascites Mouse Model Study

Jul 11, 2022, 8:30 AM EDT - 3 years ago

PharmaCyte Biotech Announces Preliminary Unaudited Financial Results for Fiscal Year 2022

Jul 11, 2022, 6:00 AM EDT - 3 years ago

IROQUOIS CAPITAL COMMENCES CONSENT SOLICITATION TO RECONSTITUTE PHARMACYTE BIOTECH BOARD OF DIRECTORS

Jul 5, 2022, 3:16 PM EDT - 3 years ago

IROQUOIS CAPITAL ISSUES STATEMENT IN RESPONSE TO RECENT ACTIONS BY THE PHARMACYTE BIOTECH BOARD OF DIRECTORS

Jul 5, 2022, 8:30 AM EDT - 3 years ago

PharmaCyte Biotech Announces Additional Quality Control Assay and Confirms Stability of CypCap Cells

Jun 23, 2022, 9:00 AM EDT - 3 years ago

IROQUOIS CAPITAL NOMINATES SLATE OF HIGHLY QUALIFIED DIRECTOR CANDIDATES FOR ELECTION AT PHARMACYTE'S 2022 ANNUAL MEETING

Jun 15, 2022, 8:30 AM EDT - 3 years ago

PharmaCyte Biotech Issues Follow-Up Response to Iroquois Capital's Second Letter on June 9 and Reiterates Commitment to Increasing Shareholder Value

Jun 13, 2022, 8:30 AM EDT - 3 years ago

PharmaCyte Biotech to Attend 2022 BIO International Convention in San Diego

Jun 9, 2022, 9:00 AM EDT - 3 years ago

IROQUOIS CAPITAL DELIVERS OPEN LETTER TO PHARMACYTE BIOTECH BOARD OF DIRECTORS

Jun 8, 2022, 8:30 AM EDT - 3 years ago

PharmaCyte Biotech Issues Response to Iroquois Capital Letter and Announces Additional Steps to Increase Shareholder Value

Jun 2, 2022, 9:00 AM EDT - 3 years ago

PharmaCyte Biotech to Implement $10-Million Share Repurchase Program

May 23, 2022, 9:00 AM EDT - 3 years ago

PharmaCyte Biotech Initiates Studies to Confirm Its Pancreatic Cancer Therapy Can Treat Malignant Ascites

May 11, 2022, 9:00 AM EDT - 3 years ago

Iroquois Capital Delivers Open Letter to PharmaCyte Biotech Board of Directors

Apr 27, 2022, 9:00 AM EDT - 3 years ago

PharmaCyte Biotech to Attend 15th International Conference on Advanced Technologies and Treatments for Diabetes

Apr 19, 2022, 9:00 AM EDT - 3 years ago

PharmaCyte Biotech Announces More Positive Tests Results for Its Pancreatic Cancer Clinical Trial Product Candidate to Satisfy FDA Requirements

Apr 13, 2022, 9:00 AM EDT - 3 years ago

PharmaCyte Biotech to Accelerate Preparations for Start of Pancreatic Cancer Clinical Trial

Apr 5, 2022, 9:00 AM EDT - 3 years ago

PharmaCyte Biotech Appoints Dr. Matthias Löhr to Board of Directors

Mar 22, 2022, 9:00 AM EDT - 3 years ago

PharmaCyte Biotech Successfully Completes 24-Month Stability Study of Its Clinical Trial Product Candidate

Mar 16, 2022, 9:00 AM EDT - 3 years ago

PharmaCyte Biotech Reports Third Quarter Financial Results and Operational Highlights

Feb 22, 2022, 9:00 AM EST - 4 years ago

PharmaCyte Biotech Announces Genetic Stability of Cytochrome P450 Gene and Site of Integration

Feb 14, 2022, 9:00 AM EST - 4 years ago

PharmaCyte Biotech Updates Status of Investigational New Drug Application to FDA

Jan 7, 2022, 2:59 AM EST - 4 years ago

Is This A Good Time To Invest In PharmaCyte?

Jan 6, 2022, 9:00 AM EST - 4 years ago

PharmaCyte Biotech to Present at H.C. Wainwright BioConnect Conference

Jan 4, 2022, 9:00 AM EST - 4 years ago

PharmaCyte Biotech Study Proves Capsule Material Is Not Toxic For Encapsulated Cells

Dec 28, 2021, 9:00 AM EST - 4 years ago

PharmaCyte Biotech Successfully Completes 36 Month Master Cell Bank Stability Study

Dec 15, 2021, 9:00 AM EST - 4 years ago

PharmaCyte Biotech Reports Second Quarter 2021 Financial Results and Operational Highlights

Dec 8, 2021, 10:16 AM EST - 4 years ago

PharmaCyte Biotech Successfully Completes Cytochrome P450 Site of Integration DNA Sequencing Assay

Nov 30, 2021, 1:05 AM EST - 4 years ago

PharmaCyte Biotech Launches Malignant Ascites Program with Commencement of Pivotal Preclinical Study

Nov 12, 2021, 9:00 AM EST - 4 years ago

PharmaCyte Biotech Announces Cell Encapsulation Technology Material Does Not Cause Skin Irritation

Sep 27, 2021, 9:00 AM EDT - 4 years ago

PharmaCyte Biotech Announces Encapsulation Material Does Not Alter Cellular DNA

Sep 21, 2021, 9:00 AM EDT - 4 years ago

PharmaCyte Biotech Releases More Positive Results From FDA-Required Biocompatibility Tests

Sep 16, 2021, 1:51 PM EDT - 4 years ago

Why Are PharmaCyte Shares Moving Higher On Thursday?

Sep 16, 2021, 9:00 AM EDT - 4 years ago

PharmaCyte Biotech Announces Positive Results of Biocompatibility Study for FDA

Sep 9, 2021, 8:57 AM EDT - 4 years ago

Why Is PharmaCyte Biotech Stock Moving Higher In Premarket Thursday?

Sep 8, 2021, 9:00 AM EDT - 4 years ago

PharmaCyte Biotech to Participate in H.C. Wainwright 23rd Annual Global Investment Conference

BillionerOfKing Nov. 11 at 3:43 PM

0 · Reply

Dfastpitchchic5 Nov. 5 at 10:19 PM

$PMCB

0 · Reply

NicoleToki632 Nov. 4 at 4:35 PM

0 · Reply

SwingNow Oct. 31 at 5:01 PM

My pick going into next week are $GSIW $ITP $PMCB $IVF . All this four gonna spike soon have fun

0 · Reply

ChaseDeluca Oct. 31 at 12:56 PM

0 · Reply

ChaseDeluca Oct. 30 at 9:16 PM

0 · Reply

BHWinehouse Oct. 30 at 1:41 PM

$QCLS $PMCB

0 · Reply

BirchTreeJJ Oct. 28 at 12:15 PM

$PMCB $QCLS buyout of assets

0 · Reply

BHWinehouse Oct. 28 at 11:46 AM

$PMCB PharmaCyte Biotech, Inc. (NASDAQ: PMCB) Special Meeting of Stockholders scheduled for Thursday, October 30, 2025 at 11:00 a.m. ET. Could be interesting $QCLS

0 · Reply

BHWinehouse Oct. 24 at 4:12 PM

0 · Reply

Pistol_Pete_P Oct. 21 at 5:30 AM

$PMCB scam

0 · Reply

BirchTreeJJ Oct. 15 at 2:16 PM

$QCLS watching $PMCB ehom I believe will acquire all of WCLS bio assets The cash from the bio assets will fund the new $TAO.X $TAOX crypto strategy @jaltucher wheres the news man. It’s long overdue.

0 · Reply

Dfastpitchchic5 Oct. 14 at 9:39 PM

$PMCB

0 · Reply

Peaceouty Oct. 14 at 8:55 PM

$SBLX we are owned by a hedge fund, and that explains the harsh price control we’ve seen today. Same with $PMCB

0 · Reply

Peaceouty Oct. 14 at 8:45 PM

$SBLX Our ceo is also the CEO of $PMCB! Woot woot! Also he’s been the assistant press secretary of the President!

1 · Reply

BHWinehouse Oct. 14 at 6:07 PM

$QCLS $PMCB

1 · Reply

BHWinehouse Oct. 14 at 4:07 PM

$QCLS $PMCB

0 · Reply

BHWinehouse Oct. 14 at 1:16 PM

$QCLS Also keep in mind, both $QCLS and $PMCB have meetings in the following weeks...

0 · Reply

BurchhausenJj Oct. 14 at 11:56 AM

$PMCB $QCLS $TAOX @BHWinehouse @Dat1099Boi yes all of that is imminent And @jaltucher as a major player This (QCLS) is a fantastic set up. Their bio assets will bring in cash. 💷 💰

0 · Reply

BHWinehouse Oct. 14 at 11:03 AM

$QCLS $PMCB What might be in the works? $QCLS will sell MYMD-1 to $PMCB in the next few weeks. Shortly after is when our first big crypto related announcement takes place. Remember, Joshua Silverman!

2 · Reply

Dfastpitchchic5 Oct. 7 at 1:04 PM

$PMCB

0 · Reply

Dfastpitchchic5 Oct. 4 at 11:18 PM

$PMCB

0 · Reply

Market Cap	5.37M
Revenue (ttm)	0.00
Net Income (ttm)	30.66M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	48,400
Avg Vol	88,586
Day's Range	N/A - N/A
Shares Out	6.80M
Stochastic %K	20%
Beta	-0.20
Analysts	Strong Buy
Price Target	N/A